Principal Financial Group Inc. Raises Position in SOPHiA GENETICS SA (NASDAQ:SOPH)

Principal Financial Group Inc. grew its stake in SOPHiA GENETICS SA (NASDAQ:SOPH) by 6.3% in the 3rd quarter, Holdings Channel.com reports. The firm owned 1,455,142 shares of the company’s stock after purchasing an additional 86,764 shares during the period. Principal Financial Group Inc.’s holdings in SOPHiA GENETICS were worth $5,290,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of SOPH. Banque Cantonale Vaudoise lifted its position in SOPHiA GENETICS by 300.0% in the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock worth $55,000 after buying an additional 9,000 shares during the last quarter. Green Alpha Advisors LLC purchased a new stake in shares of SOPHiA GENETICS in the third quarter valued at $79,000. Finally, Federated Hermes Inc. lifted its holdings in shares of SOPHiA GENETICS by 57.5% in the 2nd quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after acquiring an additional 23,000 shares during the last quarter. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Craig Hallum initiated coverage on shares of SOPHiA GENETICS in a research report on Wednesday, December 18th. They issued a “buy” rating and a $11.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, SOPHiA GENETICS has a consensus rating of “Moderate Buy” and an average target price of $7.40.

SOPHiA GENETICS Stock Down 1.3 %

Shares of SOPH opened at $3.07 on Thursday. The firm has a market capitalization of $200.70 million, a P/E ratio of -2.82 and a beta of 0.99. SOPHiA GENETICS SA has a 12-month low of $2.70 and a 12-month high of $7.37. The firm has a fifty day moving average price of $3.38 and a 200-day moving average price of $3.80. The company has a current ratio of 3.80, a quick ratio of 3.59 and a debt-to-equity ratio of 0.12.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. The company had revenue of $15.85 million during the quarter, compared to the consensus estimate of $15.90 million. During the same quarter in the prior year, the company earned ($0.21) earnings per share. Equities research analysts expect that SOPHiA GENETICS SA will post -0.98 earnings per share for the current year.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.